1
-
4
of
4
results (0.2 seconds)
Sort By:
-
2023-health-meeting-session-2c
Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore ...- Authors: Society of Actuaries
- Date: Dec 2023
- Competency: Results-Oriented Solutions
- Topics: Actuarial Profession; Experience Studies & Data; Financial Reporting & Accounting; Modeling & Statistical Methods; Predictive Analytics; Reinsurance
-
2021 Life Meeting - Session 3D: Universal Life with Secondary Guarantees: Emerging Issues and Hot Topics 8.30.21 Recording
Universal Life with Secondary Guarantees (ULSG) was first introduced in the late 1990's as low-cost, long-term death benefit protection. As this business ages, writers are experiencing ...- Authors: Society of Actuaries
- Date: Aug 2021
- Competency: Results-Oriented Solutions
- Topics: Experience Studies & Data; Life Insurance; Modeling & Statistical Methods
-
2023-health-meeting-session-5e
Every patient leaving the hospital has personal life-context circumstances that impact their chances of successful recovery and complications can be costly. Complex care management impacts over ...- Authors: Society of Actuaries
- Date: Jan 2024
- Competency: Results-Oriented Solutions
- Topics: Experience Studies & Data; Health & Disability; Technology & Applications
-
2023-health-meeting-session-1e
Anti-obesity medications have been met with reluctance from payers and employee benefits consultants who often lack analogs or empirical data to estimate the cost impact of new therapies ...- Authors: Society of Actuaries
- Date: Dec 2023
- Competency: Results-Oriented Solutions
- Topics: Experience Studies & Data; Health & Disability